权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Project 2: Structure-based antigen and nanoparticle vaccine design

项目2：基于结构的抗原和纳米颗粒疫苗设计

基本信息

批准号：
10425031
负责人：
Neil King
金额：
$ 79.3万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-02 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10425031
关键词：
2019-nCoV Achievement Antibody Response Antigens B-Cell Antigen Receptor B-Lymphocytes Biophysics COVID-19 pandemic COVID-19 vaccine Computing Methodologies Coronavirus Data Development Epitopes Evolution Fc Receptor Funding Glycoproteins Goals Human Immune response Immunity Immunization Influenza Lead Merbecovirus Methods Molecular Conformation Mosaicism Mus Mutation Performance Phase Phase I/II Clinical Trial Phylogeny Polysaccharides Positioning Attribute Production Proteins Sarbecovirus Science Secure Structure Vaccine Design Vaccines Variant Viral Work base betacoronavirus betacoronavirus vaccine biophysical properties clinical development computational pipelines coronavirus receptor coronavirus vaccine design experience influenza virus vaccine influenzavirus lead candidate mutation screening nanoparticle next generation nonhuman primate novel pandemic disease preclinical development programs prototype receptor binding response scaffold vaccine candidate virology

项目摘要

PROJECT SUMMARY – PROJECT 2: Structure-based antigen and nanoparticle vaccine design Project 2 is focused on the design, production, and characterization of novel stabilized antigens and broadly protective nanoparticle vaccines. In Aim 1, we will establish automated computational pipelines that identify sets of novel prefusion-stabilizing mutations in the spike proteins of various sarbecovirus, merbecovirus, and embecovirus strains we will use in our broadly protective vaccines. Our recent work has also demonstrated the utility of using deep mutational scanning data to guide the identification of stabilizing mutations in isolated SARS-CoV-2 receptor-binding domains (RBD). The computational pipelines we develop will extend this method to the design of additional stabilized RBD antigens across all four known clades of sarbecoviruses for use in pan-sarbecovirus vaccines. In Aim 2, we will computationally design novel self-assembling protein nanoparticle scaffolds that present prefusion spike trimers in arrays specifically designed to allow unconstrained B cell receptor/antibody access to broadly conserved epitopes. We hypothesize that these scaffolds will elicit antibody responses with superior protective breadth, particularly when used as the basis for mosaic nanoparticle immunogens. We will experimentally validate several novel nanoparticles and prototype their functional performance as monovalent nanoparticle immunogens in immunization and challenge studies in mice to identify the scaffolds that best focus the humoral immune response on conserved epitopes. In Aim 3 we will build on our recent work demonstrating the elicitation of broadly protective immune responses against influenza by generating multivalent nanoparticle vaccines displaying multiple coronavirus RBDs or prefusion spikes. We will take a hierarchical, phylogeny-driven approach. We will focus at first on developing a pan-sarbecovirus vaccine, which will display multiple RBD or prefusion spike antigens. We will then generate broadly protective merbecovirus and embecovirus vaccines displaying multiple prefusion spikes. Finally, we will define the optimal composition of a pan-betacoronavirus nanoparticle vaccine. We will work closely with the other groups in our Program to identify lead pan-sarbecovirus and pan-betacoronavirus vaccine candidates for further preclinical and clinical development at the end of Years 2 and 5 of our Program, respectively.

项目摘要-项目2：基于结构的抗原和纳米颗粒疫苗设计